Kala Pharmaceuticals Inc. (KALA)
6.33
-0.24 (-3.65%)
At close: Mar 27, 2025, 3:59 PM
6.35
0.28%
Pre-market: Mar 28, 2025, 06:31 AM EDT
Kala Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | n/a | 3.89M | 11.24M | 6.36M | 6.07M | n/a | n/a | n/a | 45K | 455K | 50K |
| Cost of Revenue | 303K | 2.56M | 4.1M | 3.17M | 2.01M | 955K | 643K | 297K | n/a | 455K | 50K |
| Gross Profit | -303K | 1.33M | 7.14M | 3.19M | 4.07M | -955K | -643K | -297K | 45K | n/a | n/a |
| Operating Income | -39.15M | -81.36M | -109.43M | -96.23M | -88.22M | -64.72M | -39.88M | -32.67M | -15.95M | -17.84M | -11.13M |
| Interest Income | 2.71M | 664K | 104K | 493K | 2.36M | 1.69M | 527K | 147K | n/a | n/a | n/a |
| Pretax Income | -42.2M | -44.82M | -142.6M | -104.33M | -94.35M | -66.74M | -42.21M | -33.17M | -16.68M | -19.36M | -10.65M |
| Net Income | -42.2M | -223K | -152.3M | -112M | -101.98M | -66.74M | -42.21M | -33.17M | -16.68M | -19.36M | -10.65M |
| Selling & General & Admin | 20.26M | 65.03M | 105.06M | 81.07M | 65.02M | 35.43M | 10.87M | 7.64M | 4.61M | 4.14M | 3.25M |
| Research & Development | 18.59M | 17.65M | 11.52M | 18.35M | 27.27M | 29.29M | 29.01M | 25.03M | 11.38M | 13.86M | 7.73M |
| Other Expenses | n/a | -926K | 1.31M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 38.85M | 82.69M | 116.58M | 99.42M | 92.29M | 64.72M | 39.88M | 32.67M | 15.99M | 18M | 10.98M |
| Interest Expense | 5.81M | 7.27M | 8.38M | 8.59M | 8.48M | 3.31M | 1.02M | 767K | 604K | 1.61M | 191K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 39.15M | 85.25M | 120.67M | 102.59M | 94.3M | 64.72M | 39.88M | 32.67M | 15.99M | 18.3M | 11.18M |
| Income Tax | n/a | -44.6M | 9.69M | 7.68M | 7.64M | 1.3M | 732K | 767K | 604K | n/a | n/a |
| Shares Outstanding (Basic) | 2.43M | 1.52M | 1.3M | 1.05M | 684.2K | 535.08K | 138.06K | 345.67K | 345.67K | 483.67K | 483.67K |
| Shares Outstanding (Diluted) | 2.43M | 1.52M | 1.3M | 1.05M | 684.2K | 535.08K | 138.06K | 345.67K | 345.67K | 483.67K | 483.67K |
| EPS (Basic) | -17.35 | -0.15 | -116.79 | -106.92 | -149.06 | -124.73 | -305.74 | -95.95 | -48.26 | -40.03 | -22.03 |
| EPS (Diluted) | -17.35 | -0.15 | -116.79 | -106.92 | -149.06 | -124.73 | -305.74 | -95.95 | -48.26 | -40.03 | -22.03 |
| EBITDA | -36.08M | -36.7M | -131.96M | -92.9M | -83.25M | -62.47M | -40.55M | -32.1M | -15.75M | -17.45M | -10.26M |
| Depreciation & Amortization | 303K | 860K | 2.27M | 2.84M | 2.62M | 955K | 643K | 297K | 330K | 298K | 201K |